Details of Disease

General Information of Disease (ID: DISTKEYK)

Disease Name	Visceral leishmaniasis
Synonyms	kala-azar, susceptibility to; kala-azar susceptibility; infection by visceral leishmaniasis; viscus leishmaniasis; kala-azar
Disease Class	1F54: Leishmaniasis
Definition	A severe form of leishmaniasis characterized by irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anemia (which may be serious). If left untreated it may lead to death. Two species of Leishmania are known to give rise to the visceral form of the disease. The species commonly found in East Africa and the Indian subcontinent is L. donovani and the species found in Europe, North Africa, and Latin America is L. infantum, also known as L. chagasi.\|Editor note: split out susceptibility/PS
Disease Hierarchy	DISABTW7: Leishmaniasis DISYKSRF: Genetic disease DISTKEYK: Visceral leishmaniasis
ICD Code	ICD-11 ICD-11: 1F54.0 ICD-10 ICD-10: B55.0 ICD-9 ICD-9: 85 Expand ICD-11 '1F54.0 Expand ICD-10 'B55.0 Expand ICD-9 85
Disease Identifiers	MONDO ID MONDO_0005445 MESH ID D007898 UMLS CUI C0023290 MedGen ID 44098 SNOMED CT ID 186803007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Miltefosine	DMND304	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LXE408	DMLBD5I	Phase 2	Small molecular drug	[2]
GSK3494245	DMSMQGL	Phase 1	Small molecule	[3]
Visceral leishmaniasis vaccine	DM4BGPN	Phase 1	NA	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 24 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
DLL1	TT9CFQD	Limited	Genetic Variation	[5]
CD58	TT5KSBY	moderate	Biomarker	[6]
CD69	TTPQE9F	moderate	Altered Expression	[7]
IL4R	TTDWHC3	moderate	Biomarker	[8]
MPL	TTIHYA4	moderate	Biomarker	[9]
ODC1	TTUMGNO	moderate	Genetic Variation	[10]
AHCY	TTE2KUJ	Strong	Biomarker	[11]
CDK12	TTJ21A9	Strong	Biomarker	[12]
CRP	TTWRN6M	Strong	Biomarker	[13]
CSF2	TTNYZG2	Strong	Biomarker	[14]
CYP51A1	TT67TDP	Strong	Biomarker	[15]
HLA-DQA1	TTU2I3J	Strong	Biomarker	[16]
HLA-DRB1	TTUXSTW	Strong	Biomarker	[17]
IFNG	TT93WF5	Strong	Genetic Variation	[18]
IL10	TTT0Q1F	Strong	Biomarker	[19]
IL9	TT0JTFD	Strong	Genetic Variation	[20]
MAPK10	TT056SO	Strong	Biomarker	[21]
MBL2	TTMQDZ5	Strong	Genetic Variation	[22]
PKD2L1	TTAHD89	Strong	Biomarker	[23]
RCE1	TT2AP5B	Strong	Biomarker	[24]
SLC6A3	TTVBI8W	Strong	Biomarker	[25]
SMPD2	TTE5VI6	Strong	Biomarker	[26]
TNF	TTF8CQI	Strong	Biomarker	[27]
CPB1	TT4UJX5	Definitive	Biomarker	[28]
------------------------------------------------------------------------------------


⏷ Show the Full List of 24 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC11A1	DT650XW	Strong	Genetic Variation	[29]
------------------------------------------------------------------------------------

This Disease Is Related to 35 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FAM120B	OTGYUFOJ	Disputed	Genetic Variation	[5]
CYTB	OTAHB98A	moderate	Genetic Variation	[30]
DDX56	OTGURA53	moderate	Biomarker	[31]
IFNGR1	OTCTQBWW	moderate	Altered Expression	[32]
IL12RB1	OTM1IJO2	moderate	Genetic Variation	[20]
LMLN	OTQF0JPY	moderate	Genetic Variation	[33]
RAB6A	OTLS86J5	moderate	Biomarker	[34]
AGMO	OTGMAHAT	Strong	Biomarker	[35]
CLEC4D	OTT7X1UC	Strong	Biomarker	[36]
CPQ	OTTNZNLD	Strong	Biomarker	[37]
DDT	OTF5HTYL	Strong	Genetic Variation	[38]
ELF2	OTEI347F	Strong	Biomarker	[39]
HSPA4	OT5HR0AR	Strong	Biomarker	[40]
IL10RA	OTOX3D1D	Strong	Therapeutic	[41]
LECT2	OTSFZ9JD	Strong	Genetic Variation	[42]
MATK	OTVOJJLJ	Strong	Altered Expression	[43]
MLST8	OT8DNJSD	Strong	Biomarker	[44]
MON2	OTCSVMAR	Strong	Genetic Variation	[45]
NUP93	OT4J2VAL	Strong	Genetic Variation	[46]
P4HB	OTTYNYPF	Strong	Biomarker	[39]
PADI1	OT13WAQX	Strong	Biomarker	[47]
PDIA2	OTC2WMXS	Strong	Biomarker	[47]
POP1	OTBIYMJ0	Strong	Genetic Variation	[44]
POPDC3	OTN4FJ5J	Strong	Biomarker	[44]
RNASE2	OT8Z4FNE	Strong	Biomarker	[48]
SGTA	OTKOJ3JB	Strong	Genetic Variation	[49]
SLAMF1	OTBTT3ZQ	Strong	Biomarker	[43]
SPAG1	OT29JZKW	Strong	Biomarker	[49]
TARS1	OT0PWST5	Strong	Biomarker	[50]
TARS2	OTXQY23P	Strong	Biomarker	[50]
TARS3	OTPMDV66	Strong	Biomarker	[50]
DUSP4	OT6WAO12	Definitive	Biomarker	[51]
EEF1B2	OTW64NPU	Definitive	Biomarker	[52]
NELFCD	OTOLTZPU	Definitive	Biomarker	[53]
PIGZ	OTAN89K5	Definitive	Biomarker	[54]
------------------------------------------------------------------------------------


⏷ Show the Full List of 35 DOT(s)

References

1	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
2	Clinical pipeline report, company report or official report of Novartis.
3	ClinicalTrials.gov (NCT04504435) A Randomized, Double-blind, Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single (in Both Fed and Fasted States) Doses of GSK3494245 in Healthy Participants. U.S.National Institutes of Health.
4	Clinical pipeline report, company report or official report of Infectious Diseases Research Institute.
5	Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India.Infect Genet Evol. 2012 Aug;12(6):1195-201. doi: 10.1016/j.meegid.2012.04.017. Epub 2012 Apr 24.
6	Leishmania donovani resistant to Ambisome or Miltefosine exacerbates CD58 expression on NK cells and promotes trans-membrane migration in association with CD2.Cytokine. 2017 Aug;96:54-58. doi: 10.1016/j.cyto.2017.02.005. Epub 2017 Mar 16.
7	Co-factor-independent phosphoglycerate mutase of Leishmania donovani modulates macrophage signalling and promotes T-cell repertoires bearing epitopes for both MHC-I and MHC-II.Parasitology. 2018 Mar;145(3):292-306. doi: 10.1017/S0031182017001494. Epub 2017 Nov 15.
8	IL-4 Mediated Resistance of BALB/c Mice to Visceral Leishmaniasis Is Independent of IL-4R Signaling via T Cells.Front Immunol. 2019 Aug 16;10:1957. doi: 10.3389/fimmu.2019.01957. eCollection 2019.
9	A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.Front Immunol. 2017 Mar 7;8:217. doi: 10.3389/fimmu.2017.00217. eCollection 2017.
10	Immunomodulation induced through ornithine decarboxylase DNA immunization in Balb/c mice infected with Leishmania donovani.Mol Immunol. 2018 May;97:33-44. doi: 10.1016/j.molimm.2018.03.004. Epub 2018 Mar 17.
11	Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.Clin Exp Immunol. 2016 Aug;185(2):165-79. doi: 10.1111/cei.12780. Epub 2016 Apr 27.
12	Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.Nature. 2018 Aug;560(7717):192-197. doi: 10.1038/s41586-018-0356-z. Epub 2018 Jul 25.
13	Prognostic value of serum C-reactive protein in kala-azar.J Trop Pediatr. 1999 Aug;45(4):226-8. doi: 10.1093/tropej/45.4.226.
14	Circulating immune complexes (IC) and IC-induced levels of GM-CSF are increased in sudanese patients with acute visceral Leishmania donovani infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis.J Immunol. 2007 Apr 15;178(8):5383-9. doi: 10.4049/jimmunol.178.8.5383.
15	Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylase.PLoS Negl Trop Dis. 2015 Mar 13;9(3):e0003588. doi: 10.1371/journal.pntd.0003588. eCollection 2015 Mar.
16	Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis.Nat Genet. 2013 Feb;45(2):208-13. doi: 10.1038/ng.2518. Epub 2013 Jan 6.
17	HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis.Immunology. 2019 Feb;156(2):174-186. doi: 10.1111/imm.13018. Epub 2018 Nov 22.
18	Influence of genetic variants of gamma interferon, interleukins 10 and 12 on Visceral Leishmaniasis in an endemic area, Iran.Pathog Glob Health. 2019 Feb;113(1):14-19. doi: 10.1080/20477724.2019.1568034. Epub 2019 Jan 15.
19	Modulation of the immune response and infection pattern to Leishmania donovani in visceral leishmaniasis due to arsenic exposure: An in vitro study.PLoS One. 2019 Feb 5;14(2):e0210737. doi: 10.1371/journal.pone.0210737. eCollection 2019.
20	Visceral leishmaniasis in two patients with IL-12p40 and IL-12R1 deficiencies.Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26362. Epub 2016 Nov 22.
21	LmjMAPK10 offers protection against Leishmania donovani infection.Parasite Immunol. 2020 Feb;42(2):e12687. doi: 10.1111/pim.12687.
22	Mannose-binding Lectin (MBL) as a susceptible host factor influencing Indian Visceral Leishmaniasis.Parasitol Int. 2015 Dec;64(6):591-6. doi: 10.1016/j.parint.2015.08.003. Epub 2015 Aug 19.
23	Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.Clin Drug Investig. 2017 Mar;37(3):259-272. doi: 10.1007/s40261-016-0481-0.
24	Evaluation of CAAX prenyl protease II of Leishmania donovani as potential drug target: Infectivity and growth of the parasite is significantly lowered after the gene knockout.Eur J Pharm Sci. 2017 May 1;102:156-160. doi: 10.1016/j.ejps.2017.03.005. Epub 2017 Mar 7.
25	Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil.Rev Soc Bras Med Trop. 2019 Apr 11;52:e20180272. doi: 10.1590/0037-8682-0272-2018.
26	Integrated genomic and metabolomic profiling of ISC1, an emerging Leishmania donovani population in the Indian subcontinent.Infect Genet Evol. 2018 Aug;62:170-178. doi: 10.1016/j.meegid.2018.04.021. Epub 2018 Apr 19.
27	Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines.Front Immunol. 2019 Apr 16;10:813. doi: 10.3389/fimmu.2019.00813. eCollection 2019.
28	Recombinant Cysteine Proteinase B from Leishmania braziliensis and Its Domains: Promising Antigens for Serodiagnosis of Cutaneous and Visceral Leishmaniasis in Dogs.J Clin Microbiol. 2019 Oct 23;57(11):e00819-19. doi: 10.1128/JCM.00819-19. Print 2019 Nov.
29	Susceptibility to leishmaniasis is affected by host SLC11A1 gene polymorphisms: a systematic review and meta-analysis.Parasitol Res. 2019 Aug;118(8):2329-2342. doi: 10.1007/s00436-019-06374-y. Epub 2019 Jun 23.
30	Possible implication of the genetic composition of the Lutzomyia longipalpis (Diptera: Psychodidae) populations in the epidemiology of the visceral leishmaniasis.J Med Entomol. 2011 Sep;48(5):1016-22. doi: 10.1603/me10249.
31	Evaluation of antileishmanial potential of computationally screened compounds targeting DEAD-box RNA helicase of Leishmania donovani.Int J Biol Macromol. 2019 Jan;121:480-487. doi: 10.1016/j.ijbiomac.2018.10.053. Epub 2018 Oct 13.
32	Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients.BMC Infect Dis. 2014 Dec 3;14:662. doi: 10.1186/s12879-014-0662-5.
33	Genetic homogeneity among Leishmania (Leishmania) infantum isolates from dog and human samples in Belo Horizonte Metropolitan Area (BHMA), Minas Gerais, Brazil.Parasit Vectors. 2015 Apr 15;8:226. doi: 10.1186/s13071-015-0837-y.
34	Leishmania major large RAB GTPase is highly immunogenic in individuals immune to cutaneous and visceral leishmaniasis.Parasit Vectors. 2017 Apr 17;10(1):185. doi: 10.1186/s13071-017-2127-3.
35	Exome Sequencing Identifies Two Variants of the Alkylglycerol Monooxygenase Gene as a Cause of Relapses in Visceral Leishmaniasis in Children, in Sudan.J Infect Dis. 2017 Jul 1;216(1):22-28. doi: 10.1093/infdis/jix277.
36	Genetic Diversity and Population Structure of Leishmania infantum from Southeastern France: Evaluation Using Multi-Locus Microsatellite Typing.PLoS Negl Trop Dis. 2016 Jan 25;10(1):e0004303. doi: 10.1371/journal.pntd.0004303. eCollection 2016 Jan.
37	A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis.Int J Parasitol. 2012 May 1;42(5):429-35. doi: 10.1016/j.ijpara.2012.02.013. Epub 2012 Mar 27.
38	Knockdown resistance mutations predict DDT resistance and pyrethroid tolerance in the visceral leishmaniasis vector Phlebotomus argentipes.PLoS Negl Trop Dis. 2017 Apr 17;11(4):e0005504. doi: 10.1371/journal.pntd.0005504. eCollection 2017 Apr.
39	Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of Leishmania (Leishmania) donovani.Front Immunol. 2019 Feb 28;10:288. doi: 10.3389/fimmu.2019.00288. eCollection 2019.
40	A comparative analysis of different molecular targets using PCR for diagnosis of old world leishmaniasis.Exp Parasitol. 2016 May;164:43-8. doi: 10.1016/j.exppara.2016.02.007. Epub 2016 Feb 16.
41	Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.Acta Trop. 2005 Mar;93(3):295-301. doi: 10.1016/j.actatropica.2004.11.008.
42	Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection.Genes Immun. 2007 Oct;8(7):539-51. doi: 10.1038/sj.gene.6364422. Epub 2007 Aug 23.
43	TNF signalling drives expansion of bone marrow CD4+ T cells responsible for HSC exhaustion in experimental visceral leishmaniasis.PLoS Pathog. 2017 Jul 3;13(7):e1006465. doi: 10.1371/journal.ppat.1006465. eCollection 2017 Jul.
44	The genetic structure of Leishmania infantum populations in Brazil and its possible association with the transmission cycle of visceral leishmaniasis.PLoS One. 2012;7(5):e36242. doi: 10.1371/journal.pone.0036242. Epub 2012 May 11.
45	Leishmania donovani causing cutaneous leishmaniasis in Sri Lanka: a wolf in sheep's clothing?.Trends Parasitol. 2009 Oct;25(10):458-63. doi: 10.1016/j.pt.2009.07.002. Epub 2009 Sep 4.
46	Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.Cytokine. 2019 Jan;113:200-215. doi: 10.1016/j.cyto.2018.07.005. Epub 2018 Jul 9.
47	Bioinformatics analysis of four proteins of Leishmania donovani to guide epitopes vaccine design and drug targets selection.Acta Trop. 2019 Mar;191:50-59. doi: 10.1016/j.actatropica.2018.12.035. Epub 2018 Dec 21.
48	The genetically determined production of the alarmin eosinophil-derived neurotoxin is reduced in visceral leishmaniasis.APMIS. 2018 Jan;126(1):85-91. doi: 10.1111/apm.12780. Epub 2017 Nov 29.
49	Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis.Mol Immunol. 2017 Nov;91:272-281. doi: 10.1016/j.molimm.2017.09.017. Epub 2017 Oct 5.
50	Genetic manipulation of Leishmania donovani threonyl tRNA synthetase facilitates its exploration as a potential therapeutic target.PLoS Negl Trop Dis. 2018 Jun 13;12(6):e0006575. doi: 10.1371/journal.pntd.0006575. eCollection 2018 Jun.
51	Immunomodulation of dual specificity phosphatase 4 during visceral leishmaniasis.Microbes Infect. 2018 Feb;20(2):111-121. doi: 10.1016/j.micinf.2017.10.009. Epub 2017 Nov 10.
52	Recombinant Leishmania eukaryotic elongation factor-1 beta protein: A potential diagnostic antigen to detect tegumentary and visceral leishmaniasis in dogs and humans.Microb Pathog. 2019 Dec;137:103783. doi: 10.1016/j.micpath.2019.103783. Epub 2019 Oct 7.
53	HIF-1 hampers dendritic cell function and Th1 generation during chronic visceral leishmaniasis.Sci Rep. 2018 Feb 22;8(1):3500. doi: 10.1038/s41598-018-21891-z.
54	Potential application of small myristoylated protein-3 evaluated as recombinant antigen and a synthetic peptide containing its linear B-cell epitope for the serodiagnosis of canine visceral and human tegumentary leishmaniasis.Immunobiology. 2019 Jan;224(1):163-171. doi: 10.1016/j.imbio.2018.09.003. Epub 2018 Sep 21.